IN THE CLAIMS

Please delete claims 3, 9 to 17 and 22 to 26.

Please amend claims 4 to 7, 18, 19 and 21 as follows:

4. (once amended) The method of claim 21, wherein said active agent is selected from the group consisting of human CGRP and rat CGRP.

5. (once amended) The method of claim 31, wherein said administration is via a pulmonary route.

E1

6. (once amended) The method of claim 21, wherein said active agent has a purity of at least 95 to 98%.

7. (once amended) The method of claim 21, wherein said active agent is dispersed within a composition comprising a pharmaceutically acceptable excipient, liquid or solid carrier.

18. (once amended) The method of claim 31, wherein said active agent has a purity of at least 95 to 98%.

E2

19. (once amended) The method of claim 31, wherein said active agent has a purity of at least 95 to 98%.

21. (once amended) A method for the treatment of asthma, wherein said method comprises the administration of an active agent selected from the group consisting of mammalian calcitonin gene-related peptide (mammalian CGRP) and mammalian [Cys(ACM)^{2,7}]CGRP.

E3

Please add new claims 27 to 36 as follows:

27. (new) The method of claim 21, wherein said active agent is selected from the group consisting of:

a) human CGRP;

b) rat CGRP;

c) human [Cys(ACM)^{2,7}]CGRP; and

d) rat [Cys(ACM)^{2,7}]CGRP.

28. (new) The method of claim 4 wherein said active agent is selected from the group consisting of human α CGRP and rat α CGRP.

29. (new) The method of claim 27, wherein said active agent is selected from the group consisting of human [Cys(ACM)^{2,7}]CGRP and rat [Cys(ACM)^{2,7}]CGRP.

30. (new) The method of claim 29, wherein said active agent is selected from the group consisting of human α [Cys(ACM)^{2,7}]CGRP and rat α [Cys(ACM)^{2,7}]CGRP.

31. (new) A method for the reduction of:

(i) agonist-induced bronchoconstriction;

(ii) agonist-induced bronchospasm;

(iii) allergen-induced bronchospasm;

(iv) lung inflammation caused by increased eosinophilia;

(v) airway hyperreactivity; or

(vi) any combination of (i) to (v);

wherein said method comprises the administration of an active agent selected from the group consisting of mammalian CGRP and mammalian [Cys(ACM)^{2,7}]CGRP.

32. (new) The method of claim 31 wherein said active agent is selected from the group consisting of:

a) human CGRP;

b) rat CGRP;

c) human [Cys(ACM)^{2,7}]CGRP); and

d) rat [Cys(ACM)^{2,7}]CGRP.

33. (new) The method of claim 32, wherein said active agent is selected from the group consisting of human CGRP and rat CGRP.

34. (new) The method of claim 33 wherein said active agent is selected from the group consisting of human α CGRP and rat α CGRP.

35. (new) The method of claim 32, wherein said active agent is selected from the group consisting of human [Cys(ACM)^{2,7}]CGRP and rat [Cys(ACM)^{2,7}]CGRP.

36. (new) The method of claim 35, wherein said active agent is selected from the group consisting of human α [Cys(ACM)^{2,7}]CGRP and rat α [Cys(ACM)^{2,7}]CGRP.

REMARKS

Claims 2, 4 to 8, 18 to 21 and 27 to 36 are pending. Applicant has cancelled claims 3, 9 to 17 and 22 to 26 without prejudice or disclaimer, amended claims 4 to 7, 18, 19 and 21, and added new claims 27 to 36.

New claim 27 has been added to to recite human and rat CGRP peptides and their [Cys(ACM)^{2,7}]CGRP forms, and claim 4 has been amended to recite human and rat CGRP peptides. Further, claims 4, 6 and 7 have been amended to depend from claim 21. Claim 21 has been amended to remove the term "adrenomedullin" and the recited bronchospastic diseases and lung inflammatory diseases. In addition, new claim 28 has been added which depends from claim 4 and recites the α forms of human and rat CGRP peptides; and new claims 29 and 30 have been added which are similar to claims 4 and 28 but are directed to the corresponding linear analogs. Applicant reserves the right to pursue any subject matter removed by these amendments in one or more continuation applications. New claim 31 has been added to recite a method for the reduction of agonist-induced bronchoconstriction and/or bronchospasm, allergen-induced bronchospasm, lung inflammation caused by increased eosinophilia, and/or airway